A5043954276- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Estrogen and related hormone effects
- Breast Cancer Treatment Studies
- Cancer Immunotherapy and Biomarkers
- Advanced Breast Cancer Therapies
- Chemokine receptors and signaling
- Breast Implant and Reconstruction
- interferon and immune responses
- Monoclonal and Polyclonal Antibodies Research
- Radiopharmaceutical Chemistry and Applications
- DNA and Nucleic Acid Chemistry
- Blood disorders and treatments
- Genomics and Chromatin Dynamics
- Platelet Disorders and Treatments
- Immunodeficiency and Autoimmune Disorders
- Breast Lesions and Carcinomas
- Nutrition, Genetics, and Disease
University of New Haven
2024
Yale University
2023-2024
Instituto Alexander Fleming
2002-2018
Hospital Privado
1989
Abstract Lung adenocarcinoma (LUAD) stands as a formidable challenge in oncology, despite the emergence of immunotherapy promising treatment avenue. The dynamic interplay between immune system and cancer plays pivotal role shaping development progression. Central to this process are neoantigens, tumor-specific antigens recognized by cytotoxic T cells, which trigger elimination tumor cells. It has been implicated that presence cells also decreases grade. However, precise impact neoantigen...
The primary breast tumors of 27 patients were analyzed for the expression estrogen receptors (ER) and DNA synthesis. Seventeen ER-positive, simultaneous ER synthesis could be in 14 ER-positive tumors. was measured through thymidine labeling index (TLI). detected by immunohistochemistry with monoclonal antibodies. In these tumors, 38.6% ± 13.1% cells (average TLI = 0.60% 0.70%), as opposed to presence 61.4% ER-negative 0.65% 0.53%). 12 both found engaged synthesis, whereas two only...
Immunoediting is a process by which developing tumors are shaped through their interaction with cells of the immune system. Tumor-specific T presumably enable outgrowth less immunogenic tumor elimination (neoantigen-expressing) ones. However this mechanism has not been directly tested because it occurs in pre-emergent stages development, before disease studied. By modifying an established mouse model soft-tissue sarcoma where emergent consistently edited, we developed system to examine...
Abstract Lung adenocarcinoma (LUAD) stands as a formidable challenge in oncology, despite the emergence of immunotherapy promising treatment avenue. The dynamic interplay between immune system and cancer plays pivotal role shaping development progression. Central to this process are neoantigens, tumor-specific antigens recognized by cytotoxic T cells, which trigger elimination tumor cells. It has been implicated that presence cells also decreases grade. However, precise impact neoantigen...
Abstract Immunoediting is the process where developing tumors are shaped by cells of immune system. Tumors with low immunogenicity likely to emerge after neoantigen-specific T eliminate most immunogenic cell populations. However, direct interrogation mechanisms which this occurs has not possible due pre-emergent nature before disease verifiably established. By modifying a mouse model soft-tissue sarcoma emergent consistently edited, we developed system examine underlying how interact tumor...
Abstract Lung adenocarcinoma (LUAD) is the leading cause of cancer-related mortality, largely due to its high prevalence rate and limited therapeutic options. Immunotherapy remains one most promising avenues, yet further research necessary enhance therapy effectiveness for a broader range patients. Central mechanism immunotherapy detection tumor neoantigens by cytotoxic T cells, which trigger elimination cells. However, it unknown how early interaction between cells neoantigen-expressing...
Abstract Sentinel Lymph Node Biopsy (SLNB) is the standard technique for axillary staging of patients with operable breast cancer and a clinically negative axilla because it avoids unwarranted dissection consequently reduces postoperative morbidity. Purpose: The aim this study to determinate feasibility accuracy second SLNB ipsilateral recurrences axilla, who were treated previously surgery axilla. Methods: Retrospective review database Instituto Alexander Fleming. Between October 2009 2014,...
Abstract Introduction: ESR1 mutations were described for the first time in 1996 when different tyrosine 537 found to confer constitutive activation of receptor, describing this region as a key factor ligand regulation ER transcriptional activity. However, due low prevalence mutation primary breast tumors its clinical significance maintained unknown. With advent large scale genomic analysis, new understanding cancer molecular characteristics has gained relevance. The been confirmed but...